Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Baxter
McKesson
Covington
QuintilesIMS
Farmers Insurance
Teva
Cantor Fitzgerald
McKinsey
Chubb

Generated: April 22, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,138,390

« Back to Dashboard

Which drugs does patent 7,138,390 protect, and when does it expire?

Patent 7,138,390 protects OCALIVA and is included in one NDA.

This patent has fourteen patent family members in eleven countries.
Summary for Patent: 7,138,390
Title:Steroids as agonists for FXR
Abstract: The invention relates to compounds of formula (I): ##STR00001## wherein R is ethyl and pharmaceutically acceptable salts, solvates or amino acid conjugates thereof. The compounds of formula (I) are useful as FXR agonists.
Inventor(s): Pellicciari; Roberto (Perugia, IT)
Assignee: Intercept Pharmaceuticals (New York, NY)
Application Number:10/471,549
Patent Claim Types:
see list of patent claims
Compound; Composition; Formulation; Use;

Drugs Protected by US Patent 7,138,390

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Intercept Pharms Inc OCALIVA obeticholic acid TABLET;ORAL 207999-001 May 27, 2016 RX Yes No ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Intercept Pharms Inc OCALIVA obeticholic acid TABLET;ORAL 207999-002 May 27, 2016 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 7,138,390

PCT Information
PCT FiledFebruary 21, 2002PCT Application Number:PCT/EP02/01832
PCT Publication Date:September 19, 2002PCT Publication Number: WO02/072598

Non-Orange Book US Patents Family Members for Patent 7,138,390

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,377,916 Steroids as agonists for FXR ➤ Sign Up
8,969,330 Steroids as agonists for FXR ➤ Sign Up
9,732,117 Steroids as agonists for FXR ➤ Sign Up
7,786,102 Steroids as agonists for FXR ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Dow
Federal Trade Commission
Citi
McKesson
Medtronic
Express Scripts
Covington
Mallinckrodt
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.